Price
No data yet.
Social Signal Score
Analyst Ratings
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 1.18
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
KOLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (12)
- Newsprnewswire.com·10d ago·Neutral
Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy Leading prostate cancer expert Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, to discuss unmet needs in metastatic castration-resistant prostate cancer (mCRPC) and the potential for therapies beyond PSMA Webinar on December 1, 2026, at 8:00 a.m.
View source ↗ - Newsglobenewswire.com·13d ago·Positive
Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intrana…
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, November 11, 2026, at 2:30 PM ET. To register, click here.
View source ↗ - Newsglobenewswire.com·25d ago·Positive
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026 MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1) associated neurofibromas, today announced that it will host a virtual key opinion leader (KOL) event, “Re…
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026 HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 20, 2026, at 2:30 PM ET.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026 NESS ZIONA, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced it will host a KOL Investor Event on SGT-610 (patidegib gel, 2%) on Wednesday, October 14, 2026 in New York.
View source ↗ - Newsglobenewswire.com·55d ago·Positive
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026 FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will host a virtual key opinion leader (KOL) event on …
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
Spectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference DALLAS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today reflected on its successful participation at the Southern Regional Burn Conference (SRBC), held September 10-12, 2026 in Williamsburg, V…
View source ↗ - Newsbusinesswire.com·75d ago·Positive
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET featuring Marcus Goncalves, MD, PhD (NYU Langone Health & Scient…
View source ↗ - Newsglobenewswire.com·96d ago·Neutral
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026
View source ↗ - Newsglobenewswire.com·97d ago·Positive
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, fe…
View source ↗ - Newsglobenewswire.com·102d ago·Positive
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it will host a KOL webinar o
View source ↗
Congress trades
No disclosed congressional trades in KOL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
